|
|
 |
|
Viewing report
|
|
|
|
Pipeline/Commercial Insight: Antihypertensives New class opportunity offset by key patent expiries
Datamonitor, July 2007, Pages: 261
Introduction
Our expects the antihypertensives market to reach almost $40 billion, across the seven major markets, by 2016. The growth will be driven by the uptake of Novartiss Tekturna, as well as increased use of ARBs, and their combinations. However, the expiries of some key patents, particularly Pfizers Norvasc and Mercks Cozaar, will restrain market growth.
Scope
Event-driven sales forecasts for 2007-16 across the seven major markets: US, France, Germany, Italy, Spain, UK and Japan. Country and market specific issues that will impact sales opportunities and market landscape, including key patent expiries and product launches. Case studies assessing the blockbuster potential of Novartiss direct renin inhibitor, Tekturna, and the impact of ESC/ESH guideline reform in Europe. Comprehensive analysis of the current antihypertensives pipeline, including a clinical and commercial assessment of all key emerging therapies.
Highlights
The growth rate of the antihypertensive market is declining. The market is mature and does not present an attractive opportunity for R&D expenditure; consequently Big Pharma are shying away from the pursuit of novel mechanisms of action in favour of developing more efficacious combination therapies. Cozaars patent expiry in the US, has the potential to alter the structure of the antihypertensive market dramatically. Threats of generic substitution and money-saving healthcare strategies which have plagued other markets, are now approaching the successful ARB class, and will have an impact on the whole antihypertensive market. Novartis is set to strengthen its position in the antihypertensives arena; Tekturna is expected to achieve international blockbuster status and Exforge will achieve sales of at least $800m, set back slightly by the premature expiry of Pfizers Norvasc patent.
Reasons to Purchase
Quantify the future size of the antihypertensives market and identify opportunities for new products. Learn how recent European healthcare reforms and guideline updates will shape the antihypertensives market. Understand the barriers to uptake for novel antihypertensive agents, and the need for paradigm shift in clinical trial design.
Customers who bought this item also bought
Forecast Insight: Antihypertensives - Key Patent Expiries Prevent Market Growth
Forecast Insight: Antihypertensives New fixed dose combinations unable to stem the tide of patent expiries
Commercial Insight: Antihypertensives - New Challenges for a Maturing Market
Antihypertensives - Two Years to Shape the Market?
Antihypertensives - Weak Pipeline Leaves Innovation to Novartis
Commercial Insight: Antihypertensives - Can Manufacturers Maintain Value?
Competitor Analysis: Antihypertensives
Commercial Insight: Antidiabetics Patent expiries and cost containment initiatives balanced by pipeline products
Pipeline Insight: Antihypertensives - Together We Stand, Divided We Fail
Commercial Insight: Migraine - Opportunities will Exist in the Wake of Generic Attack
Report on Antihypertensive Drug Market
The Pharmaceutical Market Outlook to 2018: Key Threats and Opportunities for Big Pharma and its Responses to them
|
|
|
|
